Indaptus Therapeutics (NASDAQ:INDP) Announces Earnings Results, Beats Expectations By $0.07 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings results on Monday. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07, Zacks reports.

Indaptus Therapeutics Trading Up 0.6 %

NASDAQ:INDP traded up $0.01 during mid-day trading on Wednesday, hitting $1.68. The company had a trading volume of 3,399 shares, compared to its average volume of 45,083. The business has a fifty day simple moving average of $2.17 and a 200-day simple moving average of $2.16. The firm has a market capitalization of $14.35 million, a price-to-earnings ratio of -0.94 and a beta of 1.39. Indaptus Therapeutics has a 1 year low of $1.56 and a 1 year high of $4.08.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research report on Monday, June 17th.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.